Labcorp reaffirms 2026 adjusted EPS outlook of $18.10-$18.55
LH•Labcorp reaffirms 2026 guidance
Labcorp reaffirmed 2026 guidance:
- Revenue: $14.71 billion-$14.83 billion, up 5.4%-6.3% from 2025 revenue of $13.95 billion.
- Adjusted EPS forecast: $18.10-$18.55.
- Free cash flow outlook: $1.24 billion-$1.36 billion.
- Diagnostics revenue: $11.45 billion-$11.53 billion.
- Biopharma Laboratory Services: $3.27 billion-$3.3 billion.
Long-term outlook through 2029:
- Revenue CAGR: 5%-8%.
- Adjusted EPS CAGR: 8.5%-11.5%.
- Adjusted operating margin to expand 75-150 bps.
